Back to Search
Start Over
FDA Approves Olipudase Alfa-rpcp for Acid Sphingomyelinase Deficiency: Acid sphingomyelinase deficiency is a rare, progressive genetic disease associated with significant morbidity and mortality
- Source :
- Drug Topics. November, 2022, Vol. 166 Issue 11, p38, 1 p.
- Publication Year :
- 2022
-
Abstract
- On August 31, 2022, the FDA approved olipudase alfa-rpcp (Xenpozyme) for intravenous (IV) infusion in pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), (1) a rare genetic disease that [...]
Details
- Language :
- English
- ISSN :
- 00126616
- Volume :
- 166
- Issue :
- 11
- Database :
- Gale General OneFile
- Journal :
- Drug Topics
- Publication Type :
- Periodical
- Accession number :
- edsgcl.730613278